Specifically, the service will use the company's PhysioMimix PK system to support in vitro investigations into the pharmacokinetics/pharmacodynamics (PK/PD) relationship. PhysioMimix PK uses intellectual property licensed from the Vanderbilt Institute for Integrative Biosystems Research and Education. CN Bio's oncology service will be the first implementation of the licensed technology.

The new oncology service allows researchers to create human and animal PK profiles and apply them to 3D tumor models and organoids, CN Bio said. PhysioMimix PK then exposes these 3D tumor models to the in vivo like profiles by periodically changing the drug concentration in the well, enabling researchers to study dose combinations and schedules without having to perform large and expensive xenograft studies, according to the vendor.